Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma

Summary

This is a pilot study determining the feasibility of combination treatments, pembrolizumab and stereotactic ablative radiotherapy (SBRT) in subjects with soft-tissue sarcoma. These are subjects who have metastatic disease initially, or recurrent or progressive disease that is not eligible for curative surgery.

Timeline

Start

2022-08-03

Primary completion

2025-06-27

Completion

2026-08

Publications

• Harris JP, Park J, Ku E, Seyedin S, Stitzlein R, Goldin A, Chen WP, McLaren C, Chen AM, Chow W. A Pilot Study of Pembrolizumab Combined With Stereotactic Ablative Radiotherapy for Patients With Advanced or Metastatic Sarcoma. Cancer Control. 2024 Jan-Dec;31:10732748241237331. doi: 10.1177/10732748241237331.

Drugs

Indications